Business Context and Reporting Period
This Form 8-K, filed on October 16, 2018, reports on events occurring on October 10, 2018. The registrant is Spherix Incorporated (not Dominari Holdings Inc., as noted in the metadata request). The filing details the entry into a Material Definitive Agreement, specifically a Merger Agreement with CBM Biopharma Inc. ("CBM").
Key Financial Metrics and Transaction Terms
The filing does not provide standard financial metrics such as revenue, profit, cash flow, or debt levels for either company. The primary financial data relates to the proposed merger consideration:
- Merger Consideration: Spherix will issue an aggregate of 15,000,000 shares of its common stock to CBM stockholders.
- Valuation: Each share of Spherix common stock is valued at $1.10 per share for the purpose of this transaction.
- Escrow Arrangement: 1,500,000 shares (10% of the total consideration) will be held in escrow as security for indemnification claims against Significant Company Stockholders of CBM.
- Indemnification Cap: The aggregate maximum amount of indemnification is capped at an amount equal to 1,500,000 shares.
- Basket Amount: Indemnification claims are subject to an aggregate basket of $50,000 before claims can be made.
Material Changes and Transaction Structure
The material change is the execution of the Merger Agreement. Under the terms:
- Spherix Delaware Merger Sub Inc. will merge with and into CBM, with CBM surviving as the corporation.
- All outstanding CBM stock will convert into the right to receive the Spherix stock consideration.
- Representations and warranties survive for six months post-closing, except for fraud claims which survive indefinitely.
Guidance, Risks, and Conditions
Conditions to Closing: The transaction is subject to mutual conditions including stockholder approval from both Spherix and CBM, requisite governmental approvals, and the absence of laws or litigation preventing the merger. Additionally, neither party may have experienced a "Material Adverse Effect" since the agreement date.
Termination Rights: The agreement may be terminated if the closing does not occur by April 30, 2019, if regulatory approval is permanently denied, or if a material breach remains uncured within 20 days of notice.
Risks and Forward-Looking Statements: The filing includes standard forward-looking statements regarding the likelihood of consummation and future benefits. Risks include failure to obtain regulatory or stockholder approval, delays in integration, changes in the business environment, and uncertainty regarding the long-term value of Spherix stock.
Investor Verification Checklist
- Verify the exact number of outstanding CBM shares to calculate the implied total transaction value.
- Confirm the status of stockholder approval meetings for both Spherix and CBM.
- Review the full text of the Merger Agreement (Exhibit 2.1) for specific definitions of "Material Adverse Effect" and disclosure schedules.
- Monitor for any regulatory filings or approvals required for the biopharma sector merger.
- Check subsequent filings for updates on the April 30, 2019, outside date or any termination notices.